CervoMed Inc. (CRVO)
| Market Cap | 39.26M -40.6% |
| Revenue (ttm) | 2.09M -77.6% |
| Net Income | -30.04M |
| EPS | -3.27 |
| Shares Out | 9.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108,039,749 |
| Open | 4.680 |
| Previous Close | 3.810 |
| Day's Range | 3.840 - 7.810 |
| 52-Week Range | 2.130 - 13.130 |
| Beta | -4.54 |
| Analysts | Strong Buy |
| Price Target | 19.50 (+359.91%) |
| Earnings Date | Aug 7, 2026 |
About CRVO
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant... [Read more]
Financial Performance
In 2025, CervoMed's revenue was $4.01 million, a decrease of -58.86% compared to the previous year's $9.74 million. Losses were -$26.97 million, 65.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CRVO stock is "Strong Buy." The 12-month stock price target is $19.5, which is an increase of 359.91% from the latest price.
News
CervoMed announces $10M registered direct offering priced at-the-market
CervoMed (CRVO) announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in…
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today an...
CervoMed receives notice of allowance from USPTO on neflamapimod
CervoMed (CRVO) announced that it has received a notice of allowance from the United States Patent and Trademark Office, USPTO, related to a new patent protecting the Company’s use of…
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today an...
CervoMed Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
Neflamapimod is advancing toward a pivotal phase III trial in DLB, supported by strong phase II data, regulatory alignment, and a recent financing that extends the cash runway into 2027. The company is prioritizing a strategic partnership to fund the trial and maximize value, with additional clinical catalysts expected in PPA and ALS.
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today an...
CervoMed announces $10.5M private placement
CervoMed (CRVO) announced that it has entered into a definitive securities purchase agreement for a private placement, from which the company anticipates upfront gross proceeds of approximately $10.5M...
CervoMed announces $10.5M private placement
CervoMed (CRVO) announced that it has entered into a definitive securities purchase agreement for a private placement, from which the company anticipates upfront gross proceeds of approximately $10.5M...
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies Anticip...
CervoMed Slides: Corporate presentation
CervoMed has posted slides in relation to its latest quarterly earnings report, which was published on June 10, 2026.
CervoMed price target lowered to $9 from $11 at Roth Capital
Roth Capital lowered the firm’s price target on CervoMed (CRVO) to $9 from $11 and keeps a Buy rating on the shares. The firm notes that Neflamapimod’s ability to improve…
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing
CervoMed Quarterly report: Q1 2026
CervoMed has published its Q1 2026 quarterly earnings report on May 15, 2026.
CervoMed Earnings release: Q1 2026
CervoMed released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
CervoMed Proxy statement: Proxy filing
CervoMed filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
CervoMed presents neflamapimod MRI data
CervoMed (CRVO) presented placebo-controlled magnetic resonance imaging analyses providing evidence that neflamapimod may increase the size and enhance the function of the basal forebrain in patients ...
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design
CervoMed Transcript: The 38th Annual Roth Conference
Significant progress was reported in developing a targeted therapy for DLB, with strong phase II results and a de-risked phase III trial set to launch by year-end. Biomarker-driven patient selection and updated manufacturing processes are expected to enhance efficacy and market potential.
CervoMed Slides: The 38th Annual Roth Conference
CervoMed has posted slides in relation to its latest quarterly earnings report, which was published on March 23, 2026.
CervoMed’s neflamapimod shows efficacy in dementia with DLB
CervoMed (CRVO) announced that, at the AD/PD 2026 Conference in Copenhagen, Denmark, investigators will present new analyses from the Phase 2b RewinD-LB clinical trial of neflamapimod, being developed...
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pathology — experienced greater clinical benefit wit...
CervoMed price target lowered to $11 from $19 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $11 from $19 and keeps a Buy rating on the shares. The company’s Q4/FY25 financial results…
CervoMed price target raised to $21 from $15 at Chardan
Chardan raised the firm’s price target on CervoMed (CRVO) to $21 from $15 and keeps a Buy rating on the shares. The neflamapimod program is fully back on track following…
CervoMed Earnings release: Q4 2025
CervoMed released its Q4 2025 earnings on March 17, 2026, summarizing the period's financial results.